Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations
Hematological toxicity is the most common adverse event after chimeric antigen receptor
(CAR) T-cell therapy. Cytopenias can be profound and long-lasting and can predispose for …
(CAR) T-cell therapy. Cytopenias can be profound and long-lasting and can predispose for …
[HTML][HTML] Side-effect management of chimeric antigen receptor (CAR) T-cell therapy
Highlights•CAR T cells are associated with unique side-effects.•Cytokine release syndrome
(CRS), immune effector cell-associated neurotoxicity syndrome (ICANS) and cytopenias are …
(CRS), immune effector cell-associated neurotoxicity syndrome (ICANS) and cytopenias are …
[HTML][HTML] Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow …
Background Several commercial and academic autologous chimeric antigen receptor T-cell
(CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B …
(CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B …
CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma
Hematotoxicity represents a frequent chimeric antigen receptor (CAR) T-cell–related
adverse event and remains poorly understood. In this multicenter analysis, we studied …
adverse event and remains poorly understood. In this multicenter analysis, we studied …
[HTML][HTML] The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL
K Rejeski, A Perez, G Iacoboni, O Penack… - … for immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Background CD19-directed chimeric antigen receptor T-cell therapy (CAR-T) represents a
promising treatment modality for an increasing number of B-cell malignancies. However …
promising treatment modality for an increasing number of B-cell malignancies. However …
Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma
K Wudhikarn, ML Palomba, M Pennisi… - Blood cancer …, 2020 - nature.com
CD19-targeted chimeric antigen receptor (CAR) T cell therapy is an effective treatment for
diffuse large B cell lymphoma (DLBCL). In addition to cytokine release syndrome (CRS) and …
diffuse large B cell lymphoma (DLBCL). In addition to cytokine release syndrome (CRS) and …
How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies
JA Hill, SK Seo - Blood, The Journal of the American Society of …, 2020 - ashpublications.org
Adoptive immunotherapy using B-cell–targeted chimeric antigen receptor (CAR)-modified T
cells to treat hematologic malignancies is transforming cancer care for patients with …
cells to treat hematologic malignancies is transforming cancer care for patients with …
Invasive fusariosis
M Nucci, E Anaissie - Clinical Microbiology Reviews, 2023 - Am Soc Microbiol
Invasive fusariosis is a serious invasive fungal disease, affecting immunocompetent and,
more frequently, immunocompromised patients. Localized disease is the typical clinical form …
more frequently, immunocompromised patients. Localized disease is the typical clinical form …
Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy
K Wudhikarn, MA Perales - Bone marrow transplantation, 2022 - nature.com
CD19-targeted chimeric antigen receptor (CAR) T-cell becomes a breakthrough therapy
providing excellent remission rates and durable disease control for patients with …
providing excellent remission rates and durable disease control for patients with …
Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper
I Los-Arcos, G Iacoboni, M Aguilar-Guisado… - Infection, 2021 - Springer
Chimeric antigen receptor (CAR) T-cell therapy is one of the most promising emerging
treatments for B-cell malignancies. Recently, two CAR T-cell products (axicabtagene …
treatments for B-cell malignancies. Recently, two CAR T-cell products (axicabtagene …